We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Maxcyte Inc | LSE:MXCT | London | Ordinary Share | COM STK USD0.01 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-30.00 | -7.59% | 365.00 | 360.00 | 370.00 | 389.00 | 365.00 | 389.00 | 27,565 | 16:10:17 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 41.29M | -37.92M | -0.3664 | -12.88 | 488.54M |
TIDMMXCT TIDMMXCR
RNS Number : 2057D
MaxCyte, Inc.
08 October 2018
MaxCyte, Inc.
("MaxCyte" or the "Company")
Notification of Annual General Meeting
Gaithersburg, MD - 08 October 2018: MaxCyte (LSE: MXCT, MXCR), the global cell-based medicines and life sciences company, announces that formal notice and resolutions of the Company's Annual General Meeting (AGM), along with the Annual Meeting Proxy Card and Form of Direction, has been circulated to Shareholders.
These documents are also available in electronic form on the Company's website: www.maxcyte.com.
The Annual General Meeting of Stockholders is planned to be held at 11 a.m. EDT on 31 October 2018 at 21 Firstfield Road, Suite 202, Gaithersburg, MD 20878, USA.
About MaxCyte
MaxCyte is a global cell-based medicines and life sciences company applying its patented cell engineering technology to help patients with high unmet medical needs in a broad range of conditions. MaxCyte is developing novel CARMA(TM) therapies for its own pipeline. CARMA is MaxCyte's mRNA-based proprietary platform for autologous cell therapy. In addition, through its core business, the Company leverages its Flow Electroporation(R) Technology to enable its partners across the biopharmaceutical industry to advance the development of innovative medicines, particularly in cell therapy, including gene editing and immuno-oncology. The Company has placed its cutting-edge flow electroporation instruments worldwide, with all of the top ten global biopharmaceutical companies, has more than 55 partnered programme licences in cell therapy including more than 25 licensed for clinical use. With its robust delivery technology, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com
For more information, visit www.maxcyte.com.
###
For further information, please contact:
MaxCyte Inc. Doug Doerfler, Chief Executive Officer Ron Holtz, Chief Financial Officer +1 301 944 1660 Nominated Adviser and Broker Panmure Gordon Emma Earl Freddy Crossley Ryan McCarthy Corporate Broking James Stearns +44 (0)20 7886 2500 Financial PR Adviser +44 (0)203 709 5700 Consilium Strategic Communications maxcyte@consilium-comms.com Mary-Jane Elliott Chris Welsh Sukaina Virji
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
NOADGBDGIXGBGIR
(END) Dow Jones Newswires
October 08, 2018 02:00 ET (06:00 GMT)
1 Year Maxcyte Chart |
1 Month Maxcyte Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions